ATE204176T1 - Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven - Google Patents
Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnervenInfo
- Publication number
- ATE204176T1 ATE204176T1 AT92924246T AT92924246T ATE204176T1 AT E204176 T1 ATE204176 T1 AT E204176T1 AT 92924246 T AT92924246 T AT 92924246T AT 92924246 T AT92924246 T AT 92924246T AT E204176 T1 ATE204176 T1 AT E204176T1
- Authority
- AT
- Austria
- Prior art keywords
- analogues
- insulin
- treatment
- growth factors
- optic nerve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
- A01N57/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds
- A01N57/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing acyclic or cycloaliphatic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C07F9/3813—N-Phosphonomethylglycine; Salts or complexes thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79069091A | 1991-11-08 | 1991-11-08 | |
US07/963,329 US6310040B1 (en) | 1991-11-08 | 1992-10-15 | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
PCT/US1992/009443 WO1993008826A1 (en) | 1991-11-08 | 1992-11-03 | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE204176T1 true ATE204176T1 (de) | 2001-09-15 |
Family
ID=27121062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92924246T ATE204176T1 (de) | 1991-11-08 | 1992-11-03 | Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven |
Country Status (9)
Country | Link |
---|---|
US (1) | US6310040B1 (de) |
EP (1) | EP0670729B1 (de) |
JP (1) | JP3445269B2 (de) |
AT (1) | ATE204176T1 (de) |
CA (1) | CA2122340C (de) |
DE (1) | DE69232008T2 (de) |
DK (1) | DK0670729T3 (de) |
ES (1) | ES2160581T3 (de) |
WO (1) | WO1993008826A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
JPH09509140A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 神経学的障害の治療方法 |
WO2001009327A2 (en) * | 1999-07-28 | 2001-02-08 | Genentech, Inc. | Method of preventing the injury or death of retinal cells and treating ocular diseases |
US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
EP0779927A1 (de) * | 1994-09-08 | 1997-06-25 | Chiron Corporation | Methode zur gesteigerten herstellung von insulin-ähnlichem wachstumsfaktor |
JP3191038B2 (ja) * | 1996-06-26 | 2001-07-23 | 輝夫 西田 | 眼科用医薬組成物 |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
WO1998042369A1 (fr) * | 1997-03-24 | 1998-10-01 | Fujisawa Pharmaceutical Co., Ltd. | Secretagogues de bile |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6331523B1 (en) | 1998-03-12 | 2001-12-18 | Genentech, Inc. | Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5 |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
WO2000040613A1 (en) | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
AU3737500A (en) * | 1999-03-12 | 2000-09-28 | Genentech Inc. | Method of preventing the death of retinal neurons and treating ocular diseases |
GB9928323D0 (en) * | 1999-11-30 | 2000-01-26 | Cyclacel Ltd | Peptides |
US20050245451A1 (en) * | 2000-04-05 | 2005-11-03 | Pincus Matthew R | Peptides selectively lethal to malignant and transformed mammalian cells |
EP1282437B1 (de) | 2000-05-16 | 2008-03-19 | Genentech, Inc. | Behandlung von knorpelerkrankungen |
WO2001092333A2 (en) * | 2000-05-31 | 2001-12-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of adnf for enhancing learning and memory |
BR0207422A (pt) | 2001-02-09 | 2005-04-19 | Genentech Inc | Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
DE60232880D1 (de) | 2001-05-24 | 2009-08-20 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
TWI305778B (en) * | 2001-12-03 | 2009-02-01 | Nishida Teruo | Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use |
JP4253743B2 (ja) * | 2001-12-03 | 2009-04-15 | 輝夫 西田 | 新規ペプチドおよびその医薬用途 |
EP1841443A4 (de) * | 2005-01-11 | 2012-05-02 | Heart Failure Technologies Inc | Verfahren und system zur behandlung von herzfehlern |
EP1871796A4 (de) | 2005-04-20 | 2009-01-14 | Auckland Uniservices Ltd | Vesiculine |
US8309057B2 (en) * | 2005-06-10 | 2012-11-13 | The Invention Science Fund I, Llc | Methods for elevating neurotrophic agents |
US20090169491A1 (en) * | 2006-03-06 | 2009-07-02 | Caregen Co., Ltd | Peptides Having Activities of Insulin Like Growth Factor-1 and their Uses |
US9539327B2 (en) * | 2007-11-26 | 2017-01-10 | The Research Foundation For The State University Of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
EP3187508A1 (de) * | 2008-05-07 | 2017-07-05 | BioMarin Pharmaceutical Inc. | Auf lysosomen gerichtete peptide und verwendungen davon |
BR112012000865A2 (pt) | 2009-07-17 | 2019-09-24 | T Tabor Aaron | "composição e método para a modificação genética cosmética de células substancialmente intactas" |
WO2011011073A1 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
BR112012001363A2 (pt) | 2009-07-22 | 2016-11-08 | Ipsen Pharma Sas | análogo de igf-1, composição farmacêutica,e, método para tratar condições ou doenças mediadas pela ligação do receptor de igf-1 |
TWI490371B (zh) | 2009-07-28 | 2015-07-01 | Industrie De Nora Spa | 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法 |
WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
AU2019247554A1 (en) | 2018-04-06 | 2020-11-26 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
CN111763680A (zh) * | 2019-05-22 | 2020-10-13 | 杭州杰迪生物科技有限公司 | 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU598205B2 (en) * | 1985-08-22 | 1990-06-21 | Gropep Pty Ltd | Peptide analogues of mammalian insulin-like growth factor-1 |
US4783524A (en) | 1985-09-17 | 1988-11-08 | Monsanto Company | Growth factors |
SE8505920D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | New protein and its use |
ATE112684T1 (de) | 1987-04-28 | 1994-10-15 | Boehringer Mannheim Gmbh | Verwendung von igf-ii zur behandlung von knochenkrankheiten. |
SE8703625D0 (sv) | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
DE3852636T2 (de) | 1987-12-24 | 1995-05-04 | Gropep Pty Ltd | Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2). |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
CA2114251C (en) * | 1991-08-01 | 2007-11-06 | Peter Gluckman | Igf-1 to improve the neural condition |
US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
-
1992
- 1992-10-15 US US07/963,329 patent/US6310040B1/en not_active Expired - Lifetime
- 1992-11-03 DE DE69232008T patent/DE69232008T2/de not_active Expired - Lifetime
- 1992-11-03 DK DK92924246T patent/DK0670729T3/da active
- 1992-11-03 AT AT92924246T patent/ATE204176T1/de active
- 1992-11-03 CA CA002122340A patent/CA2122340C/en not_active Expired - Lifetime
- 1992-11-03 EP EP92924246A patent/EP0670729B1/de not_active Expired - Lifetime
- 1992-11-03 WO PCT/US1992/009443 patent/WO1993008826A1/en active IP Right Grant
- 1992-11-03 JP JP50868193A patent/JP3445269B2/ja not_active Expired - Lifetime
- 1992-11-03 ES ES92924246T patent/ES2160581T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0670729A4 (de) | 1995-05-10 |
ES2160581T3 (es) | 2001-11-16 |
EP0670729B1 (de) | 2001-08-16 |
CA2122340C (en) | 2007-06-12 |
DE69232008D1 (de) | 2001-09-20 |
EP0670729A1 (de) | 1995-09-13 |
DK0670729T3 (da) | 2001-12-10 |
JP3445269B2 (ja) | 2003-09-08 |
CA2122340A1 (en) | 1993-05-13 |
WO1993008826A1 (en) | 1993-05-13 |
DE69232008T2 (de) | 2001-11-29 |
JPH07500839A (ja) | 1995-01-26 |
US6310040B1 (en) | 2001-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE204176T1 (de) | Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven | |
CA2058443A1 (en) | Treating Disorders by Application of Insulin-Like Growth Factors and Analogs | |
SE8703625D0 (sv) | New medical use | |
ATE112684T1 (de) | Verwendung von igf-ii zur behandlung von knochenkrankheiten. | |
DE3779149D1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
ATE94069T1 (de) | Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen. | |
EP1039802A4 (de) | Transdermale therapeutische vorrichtung mit capsaicin und seine analoga | |
ATE390932T1 (de) | Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
DE69203596D1 (de) | Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven. | |
ATE322283T1 (de) | Transdermale verwendung von sekretin zur behandlung von autismus | |
ATE105482T1 (de) | Behandlung von krebs mit somatostatin und mit analogen davon. | |
ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
ATE78397T1 (de) | Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration. | |
ATE220923T1 (de) | Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen | |
DE69316013D1 (de) | Verwendung von phosphinate zur behandlung der osteoporose | |
ATE108658T1 (de) | Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks. | |
ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
EP0515434A4 (en) | Method for treating intestinal diseases | |
NO933742L (no) | Humant, benavledet, insulinlignende vekstfaktorbindingsprotein | |
DE69124382D1 (de) | Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände | |
DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
DE69836689D1 (de) | Verwendung von Amylin, Adrenomedullin und deren Analoga zur Behandlung von Knorpeldefekten | |
DE3877102D1 (de) | Methode fuer die behandlung von viraler gehirnentzuendung. |